The purpose of this body of work was to characterize the ability of LY5 to inhibit STAT3 phosphorylation in a variety of sarcoma cell lines in vitro, and evaluate the pharmacokinetic (PK) and anti-tumor properties of LY5 in vivo. This evidence concerns the gene STAT3 and sarcoma.